With the long-awaited global commercialization of lazertinib, Oscotec Inc. and its US subsidiary Genosco, the originators of the novel lung cancer drug, are poised to see a steady inflow of revenues rarely seen at South Korean bioventures.
To gear up for the next phase of expected growth, Oscotec brought in Taeyoung Yoon, former head of the research...
Welcome to Scrip
Create an account to read this article
Already a subscriber?